Cp 63 -

: The Gross Motor Function Classification System (GMFCS) —the gold standard for classifying CP severity—is often the primary tool used in studies where a population size or frequency of n=63 is analyzed to determine mobility outcomes. Technical and Psychological Assessments

Beyond international protocols, "CP 63" is a recurring identifier in specialized clinical studies: : The Gross Motor Function Classification System (GMFCS)

The most significant technical reference for "CP 63" is a clinical protocol established by the European Blood Alliance and managed by the . The "CP 63" Protocol: Managing Convalescent Plasma In

While "CP 63" commonly appears in medical literature—often representing a specific patient ID (e.g., patient in heart studies) or a statistical figure (e.g., 63% of a cerebral palsy cohort)—it also refers to a vital international protocol for managing life-saving medical resources. The "CP 63" Protocol: Managing Convalescent Plasma : This framework laid the groundwork for how

In behavioral health, "CP 63" appears in the context of citation-based identifiers for specific testing tools. Researchers often utilize Child Problematic Traits Inventory (CPTI) benchmarks, frequently citing when discussing the assessment of conduct problems and psychopathic traits in young children. Summary of Key References Emergency Medicine International Convalescent Plasma Protocol NHSBT / European Blood Alliance Cardiology Patient ID for GCG Signal Pre-processing PMC Research Neurodevelopment 63% Prevalence of Speech Impairment in Bilateral CP ResearchGate Pediatric Oncology 63% Suprasellar Location for Craniopharyngioma (CP) Endocrine Society / PMC

: It was designed to coordinate European stocks of Convalescent Plasma (CP) during global health crises, such as the Ebola outbreak.

: This framework laid the groundwork for how international health bodies rapidly mobilize biological treatments during emergencies, a strategy that resurfaced during the COVID-19 pandemic for ICU patient treatments . CP 63 in Medical Research and Diagnostics